Secure CheckoutPersonal information is secured with SSL technology.
Free ShippingFree global shipping
No minimum order.
Molecular Evolutionary Models in Drug Discovery explores the application of evolutionary molecular models in drug discovery in which secondary metabolites play a fundamental role. Secondary metabolites are not produced in isolation, they are the result of the interaction of genes, metabolism and the environment. The book examines the role of secondary metabolites as leads in drug discovery and on the development of a rational bioprospecting model for new medicines based on the evolution of secondary metabolism. These evolutionary models are part of biological systems and are the most reliable expression of the functioning of living beings.
- Examines the integration and application of evolutionary models in the pharmaceutical industry to create new drug development platforms
- Investigates the biotechnological prospecting of secondary metabolites and their potential use in the discovery of new drugs
- Evaluates the ecosystem of living beings and how its molecular adaptation might improve the success of therapies
Pharmaceutical scientists; pharmacologists, researchers, biologists, medical microbiologists, bioprospectors, biodiversity researchers, biochemists, pharmacists, and clinicians, and those who are interested in drug discovery; R&D of the preclinical drug development
2. Molecular Autopoiesis
3. Natural products and molecular networks
4. Symbiogenesis autopoietic
5. Metabolomic autopoiesis
6. Clinical outcome and autopoiesis
7. Toxical autopoiesis
8. Future Research and Applications
- No. of pages:
- © Academic Press 2020
- 22nd January 2020
- Academic Press
- eBook ISBN:
- Paperback ISBN:
Dr. Bueno is currently the Chief Scientific Officer for the Research Center of Bioprospecting and Biotechnology for Biodiversity Foundation (BIOLABB). He has an MD from Caldas University, Manizales, Colombia (2001) and a Master degree in biomedical sciences from Antioquia University, Medellín, Colombia (2008). He is an expert in the design and implementation of antimicrobial platforms for to evaluate natural products and synthesis drugs with the aim of optimize in vitro antimicrobial activity selection of new chemical entities for future anti-infective pharmaceuticals. He was a Fellow, COLCIENCIAS-Universidad de Caldas (2002), a Fellow of University of the United Nations in antifungal susceptibility testing, Instituto Nacional de Enfermedades Infecciosas, INEI.ANLIS, Buenos Aires, Argentina (2004), and a Fellow, International Visitor Leadership Program on “Public Health”, United States Department of State, Bureau of Educational and Cultural Affairs (2012). He has been awarded by the Colombian Dermatology Association for best research in dermatology (2006), the Enrique Nuñez Olarte award for pharmacological research by the Colombian Pharmacology Association (2009). Author of 40 articles in pharmacological research. Author in seven chapter books in antimicrobial drug discovery.
Chief Scientific Officer, Research Center of Bioprospecting and Biotechnology for Biodiversity Foundation (BIOLABB)
Elsevier.com visitor survey
We are always looking for ways to improve customer experience on Elsevier.com.
We would like to ask you for a moment of your time to fill in a short questionnaire, at the end of your visit.
If you decide to participate, a new browser tab will open so you can complete the survey after you have completed your visit to this website.
Thanks in advance for your time.